Atlas Trials

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Clinical trial NCT01480323 · COMPLETED

Trial details

NCT number
NCT01480323
Sponsor
University Hospital Tuebingen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2012-02-01
Primary completion
2014-09-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.